

Center#1				
Sample ID	BRCA	HRD Sophia	GSS Myriad	GS AMOY
ID_1	WT	3.4 POS	40 NEG	POS 85.1
ID_2	BRCA1 p.S288Rfs*10	16.8 POS	60 POS	POS 97.4
ID_3	WT	5.3 POS	53 POS	POS91.5
ID_4	WT	(-1.6) NEG	47 POS	POS 84.3
ID_5	WT	(-3.3) NEG	28 NEG	NEG 10.7
ID_6	WT	(-11.4) NEG	3 NEG	NEG 3.3
ID_7	WT	(-18.8) NEG	18 NEG	NEG 13.3
ID_8	WT	(-10.7) NEG	16 NEG	NEG 5
ID_9	WT	(-11) NEG	15 NEG	NEG 35.4
ID_10	WT	(-1.4) NEG	23 NEG	POS 90.4
ID_11	WT	11.9 POS	75 POS	POS 99.2
ID_12	WT	(-5.4) NEG	15 NEG	NEG 7.8
ID_13	WT	12.6 POS	56 POS	POS 99.2
ID_14	WT	(-15.5) NEG	9 NEG	NEG 7.9
ID_15	WT	(-21.3) NEG	2 NEG	NEG 0.8
ID_16	WT	14.9 POS	55 POS	POS 87.9
ID_17	WT	(-5.7) NEG	34 NEG	NEG 37.1
ID_18	WT	(-12.4) NEG	19 NEG	NEG 7
ID_19	WT	8.1 POS	56 POS	POS 98.8
ID_20	WT	(-9.6) NEG	25 NEG	NEG 19.3

Supplementary table 4: Interlaboratory concordance on 20 HGSOc patients tested by adopting two commercially available NGS assays for HRD evaluation. HRD score was also compared with externalized approach (MyChoice® CDxMyriad HRD).

Abbreviations: *BRCA* (Breast Cancer Associated gene); *GSS* (Genomic Scar Score); *HRD* (Homologous Recombination Deficiency); *ID* (Identify Number); *NEG* (Negative); *POS* (Positive); *WT* (Wild-Type).